<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00484484</url>
  </required_header>
  <id_info>
    <org_study_id>P051048</org_study_id>
    <nct_id>NCT00484484</nct_id>
  </id_info>
  <brief_title>Ketamine Associated With Opioids in Refractory Cancer Pain Treatment</brief_title>
  <acronym>KETADOL</acronym>
  <official_title>Efficacy of Low Analgesic Doses of Ketamine Associated With Opioids in Refractory Cancer Pain Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Long-term opioid therapy is commonly administered for the management of severe cancer pain.
      Increasing doses of opioids are titrated against effects until analgesia is achieved or
      intolerable adverse effects occur. Ketamine, an N-methyl-D-aspartate (NMDA) receptor
      antagonist, has been reported to improve analgesia in patients with uncontrolled pain
      receiving high doses of opioids. This study aims at determining the effectiveness of ketamine
      as an adjuvant to opioids in relieving cancer pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Main objective :

      To show that low analgesic doses of ketamine associated with opioids better relieve
      refractory cancer pain than opioids without ketamine.

      Secondary objectives :

        -  Determine whether ketamine use allows to reduce opioid consumption

        -  Evaluate the adverse effects of opioids-ketamine association versus opioids-placebo.

           100 patients are expected : 50 will be treated with opioids and ketamine ; 50 will be
           treated with opioids and a placebo.

      Treatment will be administered for 4 days. Patients will be followed-up for 5 days.

      Success is defined by a decrease of the daily pain score of 50 % after 4 days. The expected
      rate of success in the placebo group is 10 % whereas the expected rate of success in the
      ketamine group is 35 %.

      Primary outcome (pain score on a 11-point numerical scale) will be evaluated everyday as well
      as secondary outcomes (patient and clinician global impression of change, opioid consumption,
      adverse reactions, patient satisfaction on pain relief, sleep interference score).

      Vital parameters (cardiac frequency, respiratory frequency and arterial blood pressure) will
      be checked everyday, many times a day : every hour for the four hours after the beginning of
      the treatment and then, every four hours ; every hour for the two hours following a dose
      shift).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Daily pain score on an 11-point numerical pain rating scale</measure>
    <time_frame>after 4 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change Clinical Global Impression of Change Daily sleep interference score Patient satisfaction of pain relief Opioids consumption Adverse effects of ketamine-opioids association</measure>
    <time_frame>during the 4 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketamine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketamine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Ketamine</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hospitalised cancer patients (informed and conscious of the cancer diagnostic)

          -  Undergoing opioid treatment for one month at least

          -  Refractory pain (score higher than 5 on an 11-point numerical pain rating scale)

          -  Ability to score pain on a numerical pain rating scale

          -  Patient written agreement

        Exclusion Criteria:

          -  Ketamine contraindications

          -  Methadone or other NMDA-antagonist treatment

          -  Karnofsky index under 10

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sylvie ROSTAING-RIGATTIERI, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2007</study_first_submitted>
  <study_first_submitted_qc>June 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2007</study_first_posted>
  <last_update_submitted>May 3, 2011</last_update_submitted>
  <last_update_submitted_qc>May 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2011</last_update_posted>
  <responsible_party>
    <name_title>Aurémie GUIMFACK</name_title>
    <organization>Department of Clinical Research of developpement</organization>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Refractory pain</keyword>
  <keyword>Uncontrolled pain</keyword>
  <keyword>Ketamine</keyword>
  <keyword>Uncontrolled cancer pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cancer Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

